Recent Updates
Recently added Catalysts
AKBA Positive Sentiment

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...

Monday, March 11, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Akebia Therapeutics plans to report its fourth quarter and full year 2023 financial results on March 14, 2024. The company will not hold a conference call due to the upcoming PDUFA target action date for vadadustat, which is under FDA review for treating anemia in chronic kidney disease patients on dialysis. Akebia aims to enhance the lives of those affected by kidney disease.
Price reaction · baseline $1.47 (2024-03-08 close) · 1 other AKBA headline(s) in the window, move may be shared
day 0 close
-2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Akebia is committed to improving the lives of patients with kidney disease.
  • The upcoming financial results may reflect positive growth and developments.
  • The review of vadadustat by the FDA could lead to significant advancements.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+1%
120-day peak, hindsight
Typical move
8%
average across 4 past catalysts
Lead asset
ferric
Phase 3 · Anemia of Chronic Kidney Disease

Full Press Release Details

CAMBRIDGE, Mass. , March 11, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA ), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to report fourth quarter and full year 2023 financial results on March 14, 2024 . Akebia will not host a conference call due to the proximity to the anticipated March 27, 2024 Prescription Drug User Fee Act (PDUFA) target action date for vadadustat, which is under review by the U.S. Food and Drug Administration as a treatment for anemia due to chronic kidney disease in adult patients on dialysis.
About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts . For more information, please visit our website at www.akebia.com , which does not form a part of this release.
Akebia Therapeutics Contact Mercedes Carrasco [email protected]

Frequently Asked Questions

When will Akebia report its financial results?

Akebia Therapeutics will report its fourth quarter and full year 2023 financial results on March 14, 2024.

Will there be a conference call for the financial results?

No, Akebia will not host a conference call due to the upcoming PDUFA target action date.

What is the PDUFA target action date for vadadustat?

The PDUFA target action date for vadadustat is March 27, 2024.

What condition is vadadustat being reviewed for?

Vadadustat is under review as a treatment for anemia due to chronic kidney disease in adult patients on dialysis.

ShareAdd on Google
Tags: AKBA Viatris Investor Conferences Healthcare Akebia Therapeutics financial results FDA review vadadustat
Last updated: Mar 11, 2024

Biotech snapshot

Cash runway
$156M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ferricPhase 3
Anemia of Chronic Kidney Disease →

Catalyst track record

+1%
best trade around AKBA's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for AKBA.

See every catalyst's timing & PoA →